Repligen corporation

Overcome common challenges. Push the boundaries of what's possible. Maximize productivity at every step.

Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. Before , Repligen maintained dual capabilities in developing pharmaceutical therapeutics drug discovery and development and the development of materials supporting biological drug manufacture bioprocessing business. Repligen employs a direct sales model to users of its products in the United States, with some sales through intermediaries in "certain foreign markets". As a consequence of current operations, about one-third each of revenue and cost and expenses are denominated in Swedish krona currency, the remaining two-thirds denominated in United States dollars ; this presents a risk to the business based on unpredictable fluctuations in currency exchange rates. The company's Protein A-related offerings are supported by proprietary technology, trade secrets and patent filings. Repligen's company headquarters are housed together with its manufacturing facility in Waltham, Massachusetts.

Repligen corporation

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in and is headquartered in Waltham, Massachusetts. Yahoo Finance. Sign in. Sign in to view your mail. Currency in USD. Amounts are as of December 31, and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.

He used to be the John D. Hunt President and CEO, repligen corporation. Viral vector N-1 intensification reduces seed train vessel number, media volume and time.

Powered by. Repligen Corp Repligen is a life science company that develops and commercializes bioprocessing technologies for the manufacturing of biological drugs. Its products include upstream and downstream filtration, chromatography products, fluid management, cell culture supplements, ligands, and operating room disposables. The company also provides solutions to overcome the development and production of modalities into a new class of drugs. Its services comprise hands-on-process and implementation consultation services. Repligen is headquartered in Waltham, Massachusetts, the US.

Tony J. Strategically, we executed on two important deals, signing a year agreement with DRS Daylight Solutions on real-time process monitoring using mid-infrared technology and more recently extending our affinity ligand relationship with Purolite an EcoLab company until Our financial guidance for the fiscal year is based on expectations for our existing business and includes the financial impact of our acquisitions. This guidance also excludes the impact of potential additional acquisitions and future fluctuations in foreign currency exchange rates. Repligen will host a conference call and webcast today, November 1, , at a. EDT, to discuss third quarter financial results, financial guidance and corporate developments. The conference call will be accessible by dialing toll-free for domestic callers or for international callers. No passcode is required for the live call.

Repligen corporation

Tony J. Strategically, our three acquisitions of Polymem, Avitide and BioFlex position us well to continue to drive above market growth in Our financial guidance for the fiscal year is based on expectations for our existing business and includes the financial impact of our acquisitions of BioFlex Solutions which closed on December 16, , Avitide Inc.

Vfs tasheel contact number

In early , Repligen licensed technology from BioFlash which it subsequently incorporated into the OPUS line of pre-packed chromatography columns. The lease on the main Waltham facility extends through Leader in Upstream Process Intensification Watch the webinars on history, potential, applications. Chief Operating Officer. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. View Repligen Corp financials. The PAT landscape in upstream intensification, the benefits of this approach, and the scale-up from benchtop to manufacturing is discussed. The reason given is: hasn't been materially touched since In September , Repligen acquired a fluid management company, Metenova. Repligen is a major supplier of Protein A , both native and recombinant forms, to the pharmaceutical industry. Telephone 1 Read More. Visit Corporate Site.

The Company will issue a press release before the market opens and will host a conference call at a.

Steel Westlake. Welcome FlexBiosys! Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. Repligen maintains manufacturing facilities in Waltham, Massachusetts and Lund, Sweden. Repligen employs a direct sales model to users of its products in the United States, with some sales through intermediaries in "certain foreign markets". Repligen is a major supplier of Protein A , both native and recombinant forms, to the pharmaceutical industry. Accelerate new modalities. Rich had been a member of the Board since Industries We Cover Your curated industry news round-up. Powered by. Tools Tools.